Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 4/20 | 0.45 |
| ▸ | PTPN7 | P35236 | 4/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.31 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6137452 | 1.00 | HMGCR (0.45) | HMGCRPTPN7RECQLTDP1DNM1 | |
| SCHEMBL6137271 | 1.00 | HMGCR (0.45) | HMGCRPTPN7RECQLTDP1DNM1 | |
| SCHEMBL6137596 | 1.00 | HMGCR (0.45) | HMGCRPTPN7RECQLTDP1DNM1 | |
| SCHEMBL6354511 | 1.00 | HMGCR (0.45) | HMGCRPTPN7RECQLTDP1DNM1 | |
| SCHEMBL6137418 | 1.00 | HMGCR (0.45) | HMGCRPTPN7RECQLTDP1DNM1 | |
| SCHEMBL6137283 | 1.00 | HMGCR (0.45) | HMGCRPTPN7RECQLTDP1DNM1 | |
| SCHEMBL6354507 | 1.00 | HMGCR (0.45) | HMGCRPTPN7RECQLTDP1DNM1 | |
| SCHEMBL6137458 | 1.00 | HMGCR (0.45) | HMGCRPTPN7RECQLTDP1DNM1 | |
| SCHEMBL6359768 | 0.98 | HMGCR (0.44) | HMGCRPTPN7RECQLTDP1 | |
| SCHEMBL6359767 | 0.98 | HMGCR (0.44) | HMGCRPTPN7RECQLTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038259-A1 | Hydroxyeicosenoic acid anaglogs | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
| EP-1425258-A4 | HYDROXYEICOSENOIC ACID ANALOGS | TAISHO PHARMACEUTICAL CO LTD (JP) | 2005-02-16 | — | — | EP | disclosed |
| EP-1436252-A4 | HYDROXYFATTYSULFONIC ACID ANALOGS | TAISHO PHARMACEUTICAL CO LTD (JP) | 2005-02-09 | — | — | EP | disclosed |
| US-20050020680-A1 | Hydroxyfattysulfonic acid analogs | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2005-01-27 | — | — | US | disclosed |
| EP-1436252-A1 | HYDROXYFATTYSULFONIC ACID ANALOGS | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2004-07-14 | — | — | EP | disclosed |
| EP-1425258-A2 | HYDROXYEICOSENOIC ACID ANALOGS | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2004-06-09 | — | — | EP | disclosed |
| WO-2003024922-A1 | HYDROXYFATTYSULFONIC ACID ANALOGS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2003-03-27 | — | — | WO | disclosed |
| WO-2003024390-A2 | HYDROXYEICOSENOIC ACID ANALOGS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020680-A1 | Hydroxyfattysulfonic acid analogs | ELANE, HRH2, APEH | HMGCR 725/4885PTPN7 3905/4885RECQL 778/4885 |
| US-20050038259-A1 | Hydroxyeicosenoic acid anaglogs | HCAR1, HRH4, HCAR3 | HMGCR 226/4885PTPN7 2459/4885RECQL 3377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.